WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection.
Transcript:
Headline News:
Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30.
Liam Martin:
Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.
One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.
COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine.
In this Sanguine Speaker Series (3) virtual fireside chat, we will discuss:
Response efforts to the current COVID-19 pandemic
How does the race for the cure affect the hundreds of other drugs in development
COVID-19’s potential impact on the global pharmaceutical market?
COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine.
Moderator:
Craig Lipset
Independent Advisor, Former Head of Clinical Innovation, Pfizer
Panelists:
Brian Neman
CEO and Co-Founder, Sanguine
Lisa Tindell
Vice President, Clinical Research Operations at Minneapolis Heart Institute Foundation
Sal Salamone
Editor in Chief, RTInsights.com
Antibodies in recovered victums’ blood may hold key to COVID-19 cure
In the race to develop treatments for the coronavirus, two California biotech companies are teaming up to collect blood samples from people who have
recovered from COVID-19 — with the hope that antibodies produced by their immune system after being infected can provide the key to developing a drug or vaccine.
Phlebotomist Teams Assisting Researchers in Select Cities
Transcript:
Trace Gallagher:
Well, phlebotomists just may be the unsung heroes in the fight against COVID-19. Teams of licensed phlebotomists in select cities are suiting up in protective gear and masks and heading into homes of former coronavirus patients.
Biotech company needs your help with advance research.
Vir Biotechnology is looking for patients in San Diego and Los Angeles counties who have recovered from COVID-19 to donate blood to help
the company find better ways to diagnose and treat the infection.
